Etodolac: Nursing Drug Guide, GI Bleeding & Renal Risk & NCLEX Review

Etodolac is available generically and was marketed as Lodine (capsules 200 mg and 300 mg; tablets 400 mg and 500 mg) and Lodine XL (extended-release tablets). Verify the MAR and home list—patients may say “Lodine” while orders list generic etodolac.

Do not confuse etodolac with other NSAIDs (ibuprofen, naproxen, meloxicam, or celecoxib) when reconciling therapy. Duplicate NSAID exposure dramatically increases GI bleeding and renal risk per NSAID class labeling.

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activity. Per prescribing information, its mechanism is not completely understood but may relate to prostaglandin synthetase inhibition. It is used for arthritis and acute pain when NSAID benefits outweigh cardiovascular, GI, and renal risks.

↔On a small screen, swipe or scroll sideways to see the full table.

Etodolac exhibits anti-inflammatory, analgesic, and antipyretic activities; like other NSAIDs, its mechanism is not completely understood but may be related to prostaglandin synthetase inhibition. It carries a boxed warning for serious cardiovascular thrombotic events and serious GI bleeding. Etodolac is eliminated primarily by the kidney; use caution in elderly patients and those with impaired renal function, and monitor renal function when therapy continues.

Use the lowest effective dose for the shortest duration consistent with treatment goals. Verify indication, renal and hepatic function, and concurrent anticoagulant, ACE inhibitor, ARB, diuretic, lithium, or methotrexate therapy before administration.

Renal impairment: Dosing adjustment is generally not required in mild to moderate renal dysfunction per labeling pharmacokinetic data, but etodolac should be used with caution because NSAIDs may further decrease renal function. Treatment is not recommended in advanced renal disease unless benefits outweigh risk; if initiated, monitor renal function closely.

Missed dose: If a scheduled dose is missed, give when remembered unless the next dose is due soon—do not double doses. For PRN acute pain, do not exceed the daily maximum per prescriber order and labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Perform medication reconciliation—screen for duplicate NSAIDs, aspirin, anticoagulants, ACE inhibitors, ARBs, and diuretics
• Review allergy history: etodolac, aspirin/NSAID reactions, aspirin-sensitive asthma, prior serious NSAID skin reactions
• Assess cardiovascular history, blood pressure, edema, renal function (BUN/creatinine), and prior GI bleeding or peptic ulcer disease
• Confirm surgical plan—hold per protocol before CABG; NSAIDs are contraindicated for CABG pain

Contraindications

• Known hypersensitivity to etodolac; previous serious skin reactions to NSAIDs (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) per labeling
• History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs (including aspirin-sensitive asthma / aspirin triad)
• Use in the setting of coronary artery bypass graft (CABG) surgery

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral capsules and tablets: Give with a full glass of water. Swallow capsules and tablets whole; do not crush or chew extended-release formulations unless pharmacy verifies an alternate method. Antacids may decrease peak concentration by 15–20% but do not change overall absorption per labeling—follow institutional timing if antacids are used routinely.

• Confirm home Lodine, OTC NSAIDs, and herbal antiplatelet supplements are documented after medication reconciliation
• Document indication, dose, route, time, and pain score before and after PRN doses
• Ensure fall-risk precautions in older adults with orthostatic symptoms or sedating co-medications
• Flag urine dipstick abnormalities—etodolac may cause false-positive urinary bilirubin or ketone results per labeling

• Improved pain score or joint stiffness with functional mobility gains in arthritis
• Reduced swelling and tenderness on joint exam when inflammation is present
• No new GI bleeding, blood pressure elevation, edema, or renal function decline while therapy continues

Hold etodolac and escalate immediately when serious NSAID complications are suspected.

• Black stool, hematemesis, coffee-ground emesis, or severe abdominal pain suggesting GI bleeding
• Chest pain, sudden weakness, facial droop, slurred speech, or other stroke or MI symptoms
• New or worsening dyspnea, rapid weight gain, or peripheral edema in patients with heart failure
• Decreased urine output, rising creatinine, or hyperkalemia suggesting acute kidney injury
• Urticaria, facial swelling, wheezing, or anaphylaxis after a dose
• Jaundice, dark urine, or persistent nausea with rising AST/ALT on liver function tests

↔On a small screen, swipe or scroll sideways to see the full table.

Symptoms following acute NSAID overdosage are typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred but were rare per etodolac tablet labeling.

Management

• No specific antidote—provide symptomatic and supportive care
• Consider emesis and/or activated charcoal (60–100 g in adults, 1–2 g/kg in children) and/or osmotic cathartic for patients seen within 4 hours with symptoms or after a large overdose (5–10 times the usual dose) per labeling
• Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding

• Etodolac vs ketorolac—similar “-olac” endings in verbal orders; read back generic name and strength
• Etodolac vs enalapril—sound-alike risk in phone orders; confirm drug class (NSAID vs ACE inhibitor)
• Lodine vs codeine—brand name confusion with opioid analgesics; verify generic etodolac on the MAR
• Duplicate NSAID therapy—scheduled etodolac plus PRN ibuprofen, naproxen, or ketorolac is a common inpatient error
• Strength errors—confirm 200/300 mg capsules versus 400/500 mg tablets; extended-release strengths differ by product
• Extended-release mix-ups—do not substitute immediate-release and extended-release etodolac without prescriber and pharmacy review

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Pain and function using structured pain assessment and mobility goals
• GI status—stool color, hemoglobin trend, and symptoms of bleeding or ulcer
• Blood pressure, weight, edema, and heart failure symptoms
• Renal function and electrolytes on BMP when diuretics, ACE inhibitors, or ARBs are co-administered
• INR and bleeding signs when anticoagulants are used
• LFTs when hepatic risk factors or symptoms are present

Document

• Dose, route, time, indication, and pain score response for PRN doses
• Allergy verification (NSAID, aspirin-sensitive asthma, prior serious skin reaction)
• Patient education on bleeding, cardiovascular symptoms, and when to seek urgent care
• Hold parameters communicated to patient and on the MAR per institutional policy

• Take exactly as prescribed—do not combine with other ibuprofen, naproxen, or aspirin products unless your prescriber directs you to
• Report black or bloody stools, vomiting blood, severe stomach pain, chest pain, shortness of breath, sudden weakness, facial swelling, or rash immediately
• NSAIDs can raise blood pressure and cause swelling—report rapid weight gain or ankle swelling
• Tell all clinicians you take etodolac before surgery, dental procedures, or new prescriptions
• Pregnancy planning: avoid NSAIDs after about 30 weeks gestation; discuss risks with your prescriber if treatment is needed earlier in pregnancy
• Breastfeeding: tell your clinician you take etodolac—an alternate pain medicine may be preferred while nursing a newborn

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for etodolac using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, ordered escalation steps, pre-administration cloze, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.